Brief Report: Factors Associated With the Selection of Initial Antiretroviral Therapy From 2009 to 2012

Autor: Andrew O. Westfall, Kenneth H. Mayer, Kitahata M, William C. Mathews, Maiese Em, Greer A. Burkholder, Michael S. Saag, Daniel R. Drozd, Cole

Publikováno v: JAIDS Journal of Acquired Immune Deficiency Syndromes. 74:60-64

We examined factors associated with selection of initial antiretroviral regimen in the CNICS cohort. Patients initiating antiretroviral therapy between July 2009 and December 2012 were classified as receiving a nonnucleoside reverse transcriptase inh

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c1c05dae060ad5755007dbb34395c276
https://doi.org/10.1097/qai.0000000000001168

Real-world use of ofatumumab to treat multiple sclerosis 9 months post-FDA approval during COVID-19 pandemic.

Autor: Coyle PK; Department of Neurology, Stony Brook University, Stony Brook, NY, 11794, USA. Electronic address: patricia.coyle@stonybrookmedicine.edu., Gorritz M; IQVIA, Wayne, PA, 19087, USA., Wade RL; IQVIA, Wayne, PA, 19087, USA., Zhou Z; IQVIA, Wayne, PA, 19087, USA., Khalid S; IQVIA, Wayne, PA, 19087, USA., Maiese EM; Novartis Pharmaceuticals Corp., East Hanover, NJ, 07936, USA., Deshpande C; Novartis Pharmaceuticals Corp., East Hanover, NJ, 07936, USA., Shao QS; Novartis Pharmaceuticals Corp., East Hanover, NJ, 07936, USA.

Publikováno v: Multiple sclerosis and related disorders [Mult Scler Relat Disord] 2023 Oct; Vol. 78, pp. 104881. Date of Electronic Publication: 2023 Jul 13.

Longitudinal adaptive immune responses following sequential SARS-CoV-2 vaccinations in MS patients on anti-CD20 therapies and sphingosine-1-phosphate receptor modulators.

Autor: Sabatino JJ Jr; UCSF Weill Institute for Neurosciences, Department of Neurology, University of California, San Francisco, CA, USA., Mittl K; UCSF Weill Institute for Neurosciences, Department of Neurology, University of California, San Francisco, CA, USA., Rowles W; UCSF Weill Institute for Neurosciences, Department of Neurology, University of California, San Francisco, CA, USA., Zamecnik CR; UCSF Weill Institute for Neurosciences, Department of Neurology, University of California, San Francisco, CA, USA., Loudermilk RP; UCSF Weill Institute for Neurosciences, Department of Neurology, University of California, San Francisco, CA, USA., Gerungan C; UCSF Weill Institute for Neurosciences, Department of Neurology, University of California, San Francisco, CA, USA., Spencer CM; UCSF Weill Institute for Neurosciences, Department of Neurology, University of California, San Francisco, CA, USA., Sagan SA; UCSF Weill Institute for Neurosciences, Department of Neurology, University of California, San Francisco, CA, USA., Alexander J; UCSF Weill Institute for Neurosciences, Department of Neurology, University of California, San Francisco, CA, USA., Mcpolin K; UCSF Weill Institute for Neurosciences, Department of Neurology, University of California, San Francisco, CA, USA., Chen P; UCSF Weill Institute for Neurosciences, Department of Neurology, University of California, San Francisco, CA, USA., Deshpande C; Novartis Pharmaceuticals, East Hanover, NJ, USA., Wyse K; Novartis Pharmaceuticals, East Hanover, NJ, USA., Maiese EM; Novartis Pharmaceuticals, East Hanover, NJ, USA., Wilson MR; UCSF Weill Institute for Neurosciences, Department of Neurology, University of California, San Francisco, CA, USA., Zamvil SS; UCSF Weill Institute for Neurosciences, Department of Neurology, University of California, San Francisco, CA, USA., Bove R; UCSF Weill Institute for Neurosciences, Department of Neurology, University of California, San Francisco, CA, USA. Electronic address: riley.bove@ucsf.edu.

Publikováno v: Multiple sclerosis and related disorders [Mult Scler Relat Disord] 2023 Feb; Vol. 70, pp. 104484. Date of Electronic Publication: 2022 Dec 28.

Real-world treatment patterns and outcomes of triple-class treated patients with multiple myeloma in the United States.

Autor: Varughese P; IntegraConnect, West Palm Beach, FL, USA., Smith R; IntegraConnect, West Palm Beach, FL, USA., Xue M; IntegraConnect, West Palm Beach, FL, USA., Dorrow N; IntegraConnect, West Palm Beach, FL, USA., Hogea C; GlaxoSmithKline, Philadelphia, PA, USA., Maiese EM; GlaxoSmithKline, Philadelphia, PA, USA., Buckingham T; GlaxoSmithKline, NC, USA.

Publikováno v: Expert review of hematology [Expert Rev Hematol] 2023 Jan; Vol. 16 (1), pp. 65-74. Date of Electronic Publication: 2022 Dec 29.

Real-world utilization and outcomes of systemic therapy among patients with advanced or recurrent endometrial cancer in the United States.

Autor: Liu J; Value, Evidence, and Outcomes, GSK, Collegeville, PA, USA., Emond B; Analysis Group, Montreal, Quebec, Canada., Maiese EM; Value, Evidence, and Outcomes, GlaxoSmithKline, Navy Yard, PA, USA., Lafeuille MH; Analysis Group, Montreal, Quebec, Canada., Lefebvre P; Analysis Group, Montreal, Quebec, Canada., Ghelerter I; Analysis Group, Montreal, Quebec, Canada., Wu C; Analysis Group, Menlo Park, CA, USA., Hurteau JA; US Medical Affairs, Women's Oncology Portfolio, GSK, Waltham, MA, USA., Thaker PH; Department of Gynecologic Oncology, Washington University School of Medicine, St. Louis, MO, USA.

Publikováno v: Current medical research and opinion [Curr Med Res Opin] 2022 Nov; Vol. 38 (11), pp. 1935-1945. Date of Electronic Publication: 2022 Aug 27.